Generic Name and Formulations:
Tigecycline 50mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution; preservative-free.
Indications for TYGACIL:
Susceptible complicated skin and skin structure and intra-abdominal infections. Community-acquired bacterial pneumonia (CABP). Limitations of use: not for treating diabetic foot infection, hospital-acquired or ventilator-associated pneumonia.
≥18yrs: Give by IV infusion over 30–60 mins. 100mg once, then 50mg every 12hrs. Skin, skin structure, and intra-abdominal infections: treat for 5–14 days. CABP: treat for 7–14 days. Severe hepatic impairment (Child Pugh C): 100mg once, then 25mg every 12hrs.
<18yrs: not recommended. See full labeling for suggested dosages when no alternative antibacterial drugs are available.
Risk of increase in all-cause mortality; reserve for use when alternatives are not suitable. Monitor for hepatic dysfunction and pancreatitis; consider discontinuing if occurs. Ventilator-associated pneumonia. Complicated intra-abdominal infections secondary to intestinal perforation: avoid monotherapy (sepsis/septic shock may develop). Avoid during tooth development; may cause permanent discoloration of the teeth. Severe hepatic impairment. Pregnancy (Cat.D): not recommended. Nursing mothers.
Monitor warfarin. May antagonize oral contraceptives.
Nausea, vomiting, diarrhea, abdominal pain, headache, increased SGPT, inj site reactions, photosensitivity, pseudotumor cerebri; pancreatitis, superinfection, anaphylaxis, C. difficile-associated diarrhea (evaluate if occurs).
Single-use vials (5mL, 10mL)—10
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC